{Reference Type}: Journal Article
{Title}: Combination and Optimal Sequencing of Systemic and Locoregional Therapies in Hepatocellular Carcinoma: Proceedings from the Society of Interventional Radiology Foundation Research Consensus Panel.
{Author}: Thornton LM;Abi-Jaoudeh N;Lim HJ;Malagari K;Spieler BO;Kudo M;Finn RS;Lencioni R;White SB;Kokabi N;Jeyarajah DR;Chaudhury P;Liu D;
{Journal}: J Vasc Interv Radiol
{Volume}: 35
{Issue}: 6
{Year}: 2024 Jun
{Factor}: 3.682
{DOI}: 10.1016/j.jvir.2024.02.017
{Abstract}: Hepatocellular carcinoma, historically, has had a poor prognosis with very few systemic options. Furthermore, most patients at diagnosis are not surgical candidates. Therefore, locoregional therapy (LRT) has been widely used, with strong data supporting its use. Over the last 15 years, there has been progress in the available systemic agents. This has led to the updated Barcelona Clinic Liver Cancer (BCLC) algorithm's inclusion of these new systemic agents, with advocacy of earlier usage in those who progress on LRT or have tumor characteristics that make them less likely to benefit from LRT. However, neither the adjunct of LRT nor the specific sequencing of combination therapies is addressed directly. This Research Consensus Panel sought to highlight research priorities pertaining to the combination and optimal sequencing of LRT and systemic therapy, assessing the greatest needs across BCLC stages.